NCT00867906View on ClinicalTrials.gov

Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Cat Allergy
Interventions
BIOLOGICAL

Cat-PAD

Cat-PAD dose 1x8 administrations 2 weeks apart

BIOLOGICAL

Placebo

Placebo comparator, 1x8 administrations 2 weeks apart

Trial Locations (1)

L5A 3V4

Alpha Medical Research, Mississauga, Toronto

Sponsors

Collaborators (1)

Adiga Life Sciences, Inc.
All Listed Sponsors
collaborator

Adiga Life Sciences, Inc.

INDUSTRY

lead

Circassia Limited

INDUSTRY

NCT00867906 - Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma | Biotech Hunter | Biotech Hunter